RT-qPCR-based microneutralization assay for human cytomegalovirus using fibroblasts and epithelial cells  by Wang, Xiao et al.
R
u
X
L
F
a
A
R
R
A
A
K
R
V
C
H
E
F
1
i
U
H
7
o
D
y
s
T
h
0Vaccine 33 (2015) 7254–7261
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
T-qPCR-based  microneutralization  assay  for  human  cytomegalovirus
sing  ﬁbroblasts  and  epithelial  cells
iao  Wang,  Keith  Peden,  Haruhiko  Murata ∗
aboratory of DNA Viruses, Division of Viral Products, Ofﬁce of Vaccines Research and Review, Center for Biologics Evaluation and Research,
ood and Drug Administration, Silver Spring, MD 20993, USA
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 12 February 2015
eceived in revised form 28 August 2015
ccepted 28 October 2015
vailable online 6 November 2015
eywords:
everse transcription quantitative PCR
irus-neutralization assay
ell lysate
uman cytomegalovirus
pithelial cell
ibroblast
a  b  s  t  r  a  c  t
Human  cytomegalovirus  (HCMV)  is a  leading  cause  of  congenital  infection  that  can  result  in serious  dis-
abilities in  affected  children.  To facilitate  HCMV  vaccine  development,  a microscale  neutralization  assay
based  on  reverse  transcription  quantitative  PCR  (RT-qPCR)  was  developed  to  quantify  HCMV-neutralizing
antibodies.  Our  approach  relies  on  the  generation  of  crude  lysates  from  virus-infected  cells  that  are
amenable  to direct  analysis  by RT-qPCR,  thereby  circumventing  rate-limiting  procedures  associated  with
sample  RNA  extraction  and  puriﬁcation.  By  serial  passaging  of  the  laboratory  HCMV  strain  AD169 in
epithelial  cells  (ARPE-19),  a revertant  virus  with  restored  epithelial  cell tropism,  designated  AD169wt131,
was  obtained.  AD169  and  AD169wt131 were  evaluated  in  both  epithelial  cells  (ARPE-19)  and  ﬁbroblasts
(MRC-5)  by  one-step  RT-qPCR  targeting  the  immediate-early  gene  IE1 transcript  of  HCMV.  Expression
kinetics  indicated  that RT-qPCR  assessment  could  be conducted  as  early  as  6 h post-infection.  Human
serum  samples  (n =  30)  from  healthy  donors  were  tested  for HCMV-speciﬁc  IgG using  a commercially
available  ELISA  and  for HCMV-neutralizing  activity  using  our RT-qPCR-based  neutralization  assay.  In
agreement  with  the ELISA  results,  higher  neutralizing  activity  was  observed  in  the  HCMV  IgG seroposi-
tive  group  when  compared  with  the  HCMV  IgG  seronegative  group.  In addition,  HCMV  IgG seropositive
human  sera  exhibited  higher neutralizing  titers  using  epithelial  cells  compared  with  using  ﬁbroblasts
(geometric  mean  titers  of  344  and  8  in ARPE-19  cells  and  MRC-5  cells,  respectively).  Our  assay  was  robust
to  variation  in input  virus  dose.  In addition,  a simple  lysis  buffer  containing  a non-ionic  detergent  was
successfully  demonstrated  to  be  a less  costly  alternative  to commercial  reagents  for  cell-lysate  prepara-
tion.  Thus,  our  rapid  HCMV  neutralization  assay  may  be  a  straightforward  and  ﬂexible  high-throughput
tool  for  measuring  antibody  responses  induced  by  vaccination  and  natural  infection.
Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://. Introduction
Human cytomegalovirus (HCMV) is a leading cause of congen-
tal infection that can result in permanent disabilities [1]. In the
nited States, 30,000 to 40,000 infants are born with congenital
CMV infection annually (∼0.6% of births), of whom more than
000 are symptomatic (a number exceeding other congenital dis-
rders for which screening is available, such as spina biﬁda and
own syndrome) [2–4]. An effective vaccine for prophylaxis is not
et available. A cost/beneﬁt analysis by the Institute of Medicine
∗ Corresponding author. Food and Drug Administration, 10903 New Hamp-
hire Avenue, Building 52/72, Room 1312, Silver Spring, MD 20993, USA.
el.: +1 240 402 9767.
E-mail address: haruhiko.murata@fda.hhs.gov (H. Murata).
ttp://dx.doi.org/10.1016/j.vaccine.2015.10.110
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-Ncreativecommons.org/licenses/by-nc-nd/4.0/).
has ranked a vaccine for HCMV to be a high priority for future
development [5].
Neutralizing antibodies may  be important for conferring protec-
tion against HCMV. Prevention of congenital HCMV infection was
observed in a non-randomized study in which HCMV hyperimmune
globulin was  administered to pregnant women with primary HCMV
infection; the transmission rate was 16% in treated women com-
pared with 40% in untreated women  [6]. However, a subsequent
randomized, placebo-controlled Phase 2 study of hyperimmune
globulin treatment in pregnant women reported a smaller effect on
transmission rate (30% with treatment vs.  44% with placebo), which
did not meet the threshold for statistical signiﬁcance [7]. Conﬁr-
mation of efﬁcacy awaits the results of other ongoing randomized
Phase 3 studies [7].
The relevant HCMV targets for neutralizing antibodies may  dif-
fer according to the cell type used in the neutralization assay. Entry
of HCMV into epithelial and endothelial cells is mediated by a viral
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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entameric complex, which contains envelope glycoproteins H and
 (gH and gL) along with pUL128, pUL130, and pUL131 [8–10].
n contrast, laboratory-adapted HCMV strains such as AD169 or
owne are propagated efﬁciently only in ﬁbroblasts; this restricted
ropism is caused by mutations in the UL131-UL128 locus that
mpair proper expression of the gH/gL/pUL128/pUL130/pUL131
omplex [8,10]. Induction of neutralizing antibodies with speci-
city towards the gH/gL/pUL128/pUL130/pUL131 complex has
een recently considered to be an important goal in HCMV vaccine
evelopment [11].
High-throughput microneutralization assays for HCMV in cur-
ent use include those based on enumerating infected cells through
mmunostaining for HCMV antigens [12,13] or measuring reporter-
ene activity expressed from an engineered virus [14,15]. No single
ssay platform has emerged as the favored consensus. In the
resent study, we have developed an alternative rapid microneu-
ralization assay for HCMV using both ﬁbroblasts and epithelial
ells. Our approach involves measuring the extent of virus infec-
ion by subjecting crude cell lysates prepared from infected cells
o direct analysis by one-step RT-qPCR. The straightforward nature
f the manipulation steps in our assay may  contribute to desir-
ble features such as robustness, adaptability to automation, and
ransferability across laboratories.
. Materials and methods
.1. Cell cultures and viruses
MRC-5 ﬁbroblasts and ARPE-19 retinal epithelial cells were
btained from American Type Culture Collection (ATCC). MRC-
 cells were maintained in Eagle’s Minimum Essential Medium
ATCC) supplemented with 10% fetal bovine serum (FBS; Hyclone).
RPE-19 cells were maintained in Advanced Dulbecco’s Modiﬁed
agle’s Medium/F12 (Life Technologies) supplemented with 10%
BS and 1X GlutaMAX (Life Technologies).
Laboratory-adapted HCMV strain AD169 was  obtained from
TCC and propagated in MRC-5 cells. To obtain a virus with restored
pithelial cell tropism, ARPE-19 cells were infected with AD169 at
 multiplicity of infection (MOI) of 1.25. Infected cells were serially
assaged as described [16]. Brieﬂy, ARPE-19 cells were passaged
eekly by mixing infected cells with uninfected cells at a ratio of
:2. Virus was collected when the cytopathic effect (CPE) of the
ells reached 100%. The revertant virus was then passaged in ARPE-
9 cells one additional time. Both AD169 and the revertant virus,
esignated as AD169wt131, were titered in MRC-5 cells through end-
oint dilution by calculating the 50% tissue culture infective dose
TCID50). The UL131 gene was PCR-ampliﬁed and sequenced for
oth AD169 and AD169wt131. AD169 matched the sequence data in
enBank (X17403 and FJ527563) and contained a single-nucleotide
rame-shifting insertion in UL131 (A at position 84 after the start
odon); AD169wt131 lacked this single-nucleotide insertion, but
as elsewhere identical to sequence data for this strain in GenBank.
.2. Antibodies for neutralization assays
A neutralizing mouse monoclonal anti-gH antibody (clone 51C1)
as obtained from a commercial source (Acris Antibodies; San
iego, CA, USA). Thirty individual serum samples from healthy male
onors ranging in age from 20 to 63 were obtained from Valley
iomedical (Winchester, VA, USA). The presence of IgG antibodies
gainst HCMV in the serum samples was evaluated using a com-
ercial ELISA kit (Zeus Scientiﬁc; ELISA Cytomegalovirus IgG Test;
aritan, NJ, USA). Serum samples were heat-inactivated at 56 ◦C for
0 min  prior to assessing HCMV-neutralizing activity to inactivate
omplement. (2015) 7254–7261 7255
2.3. RT-qPCR-based microneutralization assay
Cell monolayers (MRC-5 or ARPE-19) were prepared by seed-
ing 96-well culture plates (15,000 cells per well). On the following
day, 2-fold serial dilutions of antibody or serum were made in the
appropriate base culture medium supplemented with 1% FBS and
then mixed with equal volume of virus (AD169 or AD169wt131).
Unless otherwise indicated, the ﬁnal input of virus in each well
(pre-neutralization) was 1000 TCID50. After incubation at 37 ◦C for
1 h, the mixtures were transferred to cells in the 96-well plates.
Cells were incubated for an additional 6 h and then washed twice
with phosphate-buffered saline (100 L per well). Cell lysates were
generated using iScript Sample Preparation Reagent (Bio-Rad) or
Cell-Lysis (CL) Buffer containing 10 mM Tris-HCl, pH 7.4, 0.25%
Igepal CA-630, and 150 mM NaCl [17]. After exposure of cells to lysis
reagent (100 L per well) at room temperature (22 ◦C) for 2 min,
the resulting cell lysates were carefully collected and stored frozen
until analysis by RT-qPCR.
SYBR Green-based RT-qPCR analysis was performed using
the iScript One-Step RT-PCR kit (Bio-Rad). UL123 and UL89
were chosen as gene targets for RT-qPCR detection with one
of the primers from each pair spanning an exon–exon junc-
tion. Both primer pairs were designed using QuantPrime [18].
Primers for UL123 were AGATGTCCTGGCAGAACTCGTC (for-
ward) and TTCTATGCCGCACCATGTCCAC (reverse). Primers for
UL89 were CCAGTTGCTACAACACCAACAGC (forward) and AGGC-
CTCTTTCTTGATGAAGTGC (reverse). The amplicon size was  62 bp
for UL123 and 87 bp for UL89. The ﬁnal RT-qPCR mixture contained
1X iScript One-Step SYBR Green RT-PCR mix, 300 nM each of for-
ward and reverse primer, 0.2 L of iScript reverse transcriptase,
1 L of sample cell lysate, and water to 10 L. RT-qPCR cycling pro-
tocol using the CFX-96 instrument (Bio-Rad) was as follows: 50 ◦C
for 10 min  (1X); 95 ◦C for 5 min  (1X); and 95 ◦C for 10 s, 65.5 ◦C
(UL123) or 61.5 ◦C (UL89) for 30 s (40X). An RNA standard was
obtained by purifying total RNA from AD169-infected MRC-5 cells
using the RNeasy kit (Qiagen). For each run, a 10-fold dilution series
of RNA standard (using cell lysate from uninfected cells as the dilu-
ent) was included to aid in quantiﬁcation; negative controls (lysates
from uninfected cells) and no-reverse transcription controls were
also included. Ampliﬁcation efﬁciency usually ranged between 90%
and 105%. The neutralization endpoint was deﬁned as the concen-
tration (IC90) or fold-dilution (NT90) of antibody/serum necessary
for 90% inhibition of RT-qPCR signal in comparison with virus con-
trol samples (infected cells in the absence of neutralizing activity).
IC90 or NT90 values were estimated by linear interpolation derived
from the two experimental dilutions immediately above and imme-
diately below the threshold for neutralization.
2.4. Immunostaining-based microneutralization assay
ARPE-19 cell monolayers, serum dilutions, and cell infections
(using AD169wt131) were prepared as described in the RT-qPCR-
based microneutralization assay. Infected cells were incubated
at 37 ◦C for 18 h. Immunostaining was performed as described
by Abai et al. [12] with minor modiﬁcations. Brieﬂy, cells were
washed once with PBS and ﬁxed with absolute ethanol for 20 min.
Blocking was  performed with 2% horse serum for 1 h, followed
by treatment with 0.3% hydrogen peroxide in PBS for 30 min
to quench endogenous peroxidase activity. After washing with
PBS three times, cells were incubated with the primary anti-IE1
monoclonal antibody (MAB810; Millipore) at a concentration of
0.1 g/mL for 1 h. The secondary biotinylated anti-mouse IgG
antibody and VECTASTAIN ABC reagent were prepared as recom-
mended by the supplier (Vector Laboratories; Burlingame, CA,
USA). 3,3′,5,5′-tetramethylbenzidine (TMB; Vector Laboratories)
was used as the peroxidase substrate. After allowing the stain
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cig. 1. IE1 transcription of HCMV in (A) MRC-5 ﬁbroblasts and (B) ARPE-19 epithel
o  inoculate seeded cells in 96-well plates (15,000 cells/well) using a TCID50 of 100
,  3, 6, 12, or 24 h post-infection and subjected to SYBR Green one-step RT-qPCR an
umbers were normalized to the mean value at 1 h post-infection. Each point repre
ntensity to develop for 5 min, the plates were rinsed, dried, and
canned using the ImmunoSpot instrument (CTL; Shaker Heights,
H, USA). The IE1-positive cells were analyzed and counted using
he BioSpot 5.0 software (CTL). The neutralization endpoint was
eﬁned as the fold-dilution (NT90) of serum resulting in 90%
nhibition of infected foci in comparison with virus control wells
n the absence of neutralizing activity.
. Results
.1. Adaptation of a laboratory HCMV strain to restore epithelial
ell tropism
The tropism of laboratory-adapted HCMV strain AD169 is
estricted to ﬁbroblasts; this property results from a single base-
air insertion in the gene UL131 [8,10]. AD169 was serially
assaged in ARPE-19 cells to rescue its epithelial cell tropism. At
assage 6, extensive CPE was observed. Cell-free revertant virus,
esignated as AD169wt131, was collected and sequencing conﬁrmed
hat the complete open reading frame of UL131 was restored by
emoval of the single base-pair insertion found in the parental virus.
.2. Optimization of RT-qPCR for HCMV detection in cell cultureTo develop an RT-qPCR-based microneutralization assay for
CMV, we adapted an approach that we had successfully applied
o study RNA viruses [19,20]. Our assay relies on generating crude
ell lysates that can be directly used for RT-qPCR. Cell-lysate
ig. 2. Linear range of HCMV IE1 RT-qPCR in (A) MRC-5 ﬁbroblasts and (B) ARPE-19 epit
lates  (15,000 cells/well). Input virus TCID50 ranged from 125 to 8000 (two-fold series). 
t  6 h post-infection followed by RT-qPCR analysis. Copy numbers were normalized agai
orresponding range (n = 3).ls. Laboratory-adapted strain AD169 and its revertant virus AD169 were used
l lysates were prepared using iScript Sample Preparation Reagent and collected at
 with primers targeting the HCMV immediate-early gene IE1 transcript. RNA copy
 the mean with corresponding range (n = 3).
preparation involves the following straightforward steps: (1) cell
washing, (2) cell exposure to lysis reagent, and (3) collection of
lysates for immediate analysis or frozen storage. The transcript of
the immediate-early gene IE1 (UL123) was  chosen as the target
for RT-qPCR. One of the primers was  designed to span the splice
junction between exons 3 and 4 to detect target viral RNA specif-
ically. No ampliﬁcation from viral genomic DNA was observed
as demonstrated by control reactions in the absence of reverse
transcriptase (data not shown).
IE1 transcription of AD169 and AD169wt131 was evaluated by RT-
qPCR using MRC-5 ﬁbroblasts and ARPE-19 epithelial cells grown
in 96-well plates (15,000 cells per well; 1000 TCID50 of virus per
well). Cell lysates were prepared at indicated times after infection
using a commercial cell lysis reagent (Bio-Rad) and directly sub-
jected to one-step SYBR Green RT-qPCR. AD169wt131 was capable
of infecting both MRC-5 and ARPE-19 cells with the RT-qPCR signal
nearing a plateau as early as 6 h post-infection (Fig. 1). In contrast,
the parental AD169 was  only able to infect efﬁciently MRC-5 cells
(Fig. 1A); signal accumulation was  modest in AD169-infected ARPE-
19 cells, reﬂecting its deﬁciency in epithelial cell tropism (Fig. 1B).
The observed kinetics supported using the 6-h time point for end-
point assessment in our neutralization assay.
We further evaluated the relationship between RT-qPCR signal
and input virus quantity. MRC-5 and ARPE-19 cells were infected
with either AD169 or AD169wt131 (2-fold increments ranging from
125 to 8000 TCID50 per well), and the IE1 transcript was  quan-
tiﬁed at 6 h post-infection. In ARPE-19 cells, the RT-qPCR signal
increased according to input AD169wt131 in an approximately linear
helial cells. AD169 and AD169wt131 were used to inoculate seeded cells in 96-well
Cell lysates were prepared using iScript Sample Preparation Reagent and collected
nst the mean value of AD169 at 125 TCID50. Each point represents the mean with
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anner (Fig. 2B). However, in MRC-5 cells, linearity between virus
nput and RT-qPCR signal was observed at or below 1000 TCID50
er well (Fig. 2A). Thus, the standard input virus dose for our neu-
ralization assay was chosen to be 1000 TCID50 per well to remain
ithin the linear range while maximizing signal detectable at 6 h
ost-infection.
.3. HCMV-neutralizing activity of a monoclonal anti-gH
ntibody
The neutralizing activity of a commercially available mono-
lonal anti-gH antibody (clone 51C1) was determined in MRC-5
ells using both AD169 and AD169wt131, and in ARPE-19 cells using
D169wt131. Two-fold serial dilutions of the antibody were incu-
ated with equal volume of virus. The virus-antibody mixtures
ere then transferred to previously seeded cell-culture plates. Cell
ysates were collected after 6 additional hours of incubation and
eutralization was assessed by RT-qPCR. A comparison of neutraliz-
ng activity in MRC-5 ﬁbroblasts (Fig. 3A) revealed that the anti-gH
ntibody exhibited a higher potency (lower IC90) against AD169
1.5 g/mL) than against AD169wt131 (9.7 g/mL). In contrast, the
ifference in neutralizing activity against AD169wt131 was  within
-fold across cell types (Fig. 3A and B). Data generated using a
onoclonal antibody with known speciﬁcity to HCMV support the
easibility of measuring virus neutralization using our RT-qPCR-
ased assay. Furthermore, the gH associated with AD169 appears
o be more efﬁciently targeted for neutralization by the anti-gH
ntibody 51C1 compared with the gH associated with AD169wt131,
ossibly due to occlusion of the gH epitope in AD169wt131.
.4. HCMV-neutralizing activity of human serum samples
Thirty human serum samples from healthy male donors were
ested for HCMV-neutralizing activity using AD169wt131 in both
RC-5 and ARPE-19 cells. We  ﬁrst investigated whether theseerum samples contained HCMV-speciﬁc IgG antibodies using a
ommercial ELISA. The 30 samples were organized into two groups
Supplemental Table 1): HCMV IgG seropositive (n = 22) and HCMV
gG seronegative (n = 8).
ig. 3. HCMV-neutralizing activity of an anti-gH monoclonal antibody (51C1) assessed by
olume of virus for 1 h. The virus–antibody mixtures were then transferred to 96-well cultu
irus  quantity was 1000 TCID50 per well. Cell lysates were prepared using iScript Sample Pr
eutralization endpoint (IC90) was deﬁned as the antibody concentration necessary for 
n  the absence of neutralizing activity). Each point represents the mean with correspondi (2015) 7254–7261 7257
Concordance was  observed between neutralizing activity of sera
measured in ARPE-19 cells and HCMV IgG serostatus determined by
ELISA (Fig. 4A). HCMV IgG positive sera were associated with sub-
stantial neutralizing activity against AD169wt131 in ARPE-19 cells
(NT90 ranging from 21 to 1880). In contrast, HCMV IgG negative
sera were associated with substantially lower neutralizing activ-
ity (NT90 ranging from <10 to 47). Geometric mean titers (GMTs)
in ARPE-19 cells were 344 and 7 for positive and negative sera,
respectively (Fig. 4A; NT90 titers <10 were assigned a value of 5).
A marked difference in neutralizing activity was  observed in MRC-
5 cells compared with ARPE-19 cells. GMTs in MRC-5 cells were
8 and 5 for positive and negative sera, respectively (Fig. 4A; NT90
titers <10 were assigned a value of 5). Neutralization data in both
ARPE-19 and MRC-5 cells for a representative sample (#11) are
shown in Fig. 4B; titers for this sample were 1880 and 28 in ARPE-19
cells and MRC-5 cells, respectively. For samples with determinable
titers using both cell types (n = 7; Supplemental Table 1), the mean
fold-change in titer (ARPE-19/MRC-5) was 47 (ranging from 12 to
67). The results suggest that sera obtained following natural infec-
tion exhibit higher HCMV-neutralizing activity in epithelial cells
compared with ﬁbroblasts.
Neutralization results obtained using our RT-qPCR-based
approach were compared with those obtained using an approach
based on immunostaining cells expressing IE1 [12]. The data are
shown in Fig. 4C. Using serum samples with measurable neutral-
ization titers in both assays in ARPE-19 cells (n = 24; six samples
had titers of <10 in both assays), a high degree of correlation was
observed (r = 0.99).
To conﬁrm our neutralization results, we  applied our RT-qPCR-
based approach using UL89 as an alternative target. UL89 is
reported to be expressed with early-late kinetics [21] and encodes
a subunit of terminase [22]. Again, one of the primers for UL89
spanned an exon–exon junction, thereby allowing viral UL89 RNA
to be speciﬁcally detected. Neutralization of AD169wt131 with UL89
RNA as the detection target was assessed at 72 h post-infection
in ARPE-19 cells using a subset of our serum samples (#11, #15,
#21, and #26); neutralization results were comparable with those
obtained using IE1 RNA as the detection target (Supplemental Fig.
1 and Supplemental Table 1).
 RT-qPCR. Two-fold serial dilutions of anti-gH antibody were incubated with equal
re plates of (A) MRC-5 cells or (B) ARPE-19 cells such that the ﬁnal pre-neutralization
eparation Reagent and collected at 6 h post-infection followed by RT-qPCR analysis.
90% inhibition of RT-qPCR signal compared with virus control wells (infected cells
ng range (n = 2).
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Fig. 4. HCMV-neutralizing activity of human serum samples assessed by RT-qPCR. Two-fold serial dilutions of human sera were incubated with equal volume of virus
(AD169wt131) for 1 h. The virus-serum mixtures were then transferred to 96-well culture plates of MRC-5 or ARPE-19 such that the ﬁnal pre-neutralization virus quantity was
1000  TCID50 per well. Cell lysates were prepared using iScript Sample Preparation Reagent and collected at 6 h post-infection followed by RT-qPCR analysis. Neutralization
titer  (NT90) was  deﬁned as the dilution of serum necessary for 90% inhibition of RT-qPCR signal compared with virus control wells (infected cells in the absence of neutralizing
activity). (A) Neutralization results from the entire collection of samples (n = 30; 22 seropositives and 8 seronegatives) are summarized. Individual titers as well as geometric
mean  titers (GMTs) for each group are shown according to cell type used in the assay (MRC-5 or ARPE-19). For this analysis, samples with titers below the lowest dilution
(<1:10) were assigned a value of 5. (B) Neutralization results from one representative serum sample (#11) are shown. Each point represents the mean with corresponding range
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[n  = 2). (C) RT-qPCR-based neutralization results are compared with neutralization
eutralization titers in both assays in ARPE-19 cells; n = 24; Pearson’s correlation co
.5. Assay compliance with the percentage law
We  investigated whether the performance of our microneutral-
zation assay conforms to predictions according to the percentage
aw [23] (i.e., regardless of virus input, the proportion of virus neu-
ralized by a given concentration of antibody remains constant).
wo human serum samples, #11 and #21, were tested in ARPE-19
ells using a range of input virus doses (1000, 2000, 4000, or 8000
CID50 of AD169wt131). Titers of both sera were minimally affected
within 2-fold) by changes in input virus dose. The NT90 values
anged from 1188 to 1834 for sample #11 (Fig. 5A) and from 517
o 936 for sample #21 (Fig. 5B). The results suggest that our assay
s relatively robust to perturbations in input virus dose.
.6. A simple cell-lysis buffer as an alternative to commercial
eagentsWe  previously reported that a simple cell-lysis buffer (CL Buffer)
ontaining a non-ionic detergent (0.25% Igepal CA-630) worked
ffectively for preparation of cell lysates that are RT-qPCR-ready
17]. Samples for our assay were generated using CL Buffer, ands based on immunostaining cells expressing IE1 (serum samples with measurable
nt r = 0.99).
neutralization results were compared with those obtained using
the commercial cell-lysis reagent (Bio-Rad). The monoclonal anti-
gH antibody 51C1 was  tested in MRC-5 cells using AD169 and in
ARPE-19 cells using AD169wt131. A subset of human serum sam-
ples (#11, #15, #21, and #26) were tested in ARPE-19 cells using
AD169wt131. For the monoclonal anti-gH antibody 51C1, the IC90s
obtained using CL Buffer were 1.6 g/mL for AD169 and 9.4 g/mL
for AD169wt131 (Supplemental Fig. 2A), consistent with values
obtained using the commercial reagent (Fig. 3). In addition, all four
sera tested using CL Buffer were associated with titers comparable
with those obtained using the commercial reagent (Supplemental
Fig. 2B and Supplemental Table 1). We  conclude that CL Buffer is
a suitable and less costly alternative for generating samples to be
used in our neutralization assay.
4. DiscussionWe  have recently developed neutralization assays for sev-
eral viruses with endpoint assessment determined by qPCR.
We have emphasized an approach that can be used in
X. Wang et al. / Vaccine 33 (2015) 7254–7261 7259
Fig. 5. Neutralization of HCMV is consistent with the percentage law. Two-fold serial dilutions of individual human serum samples were incubated with varying quantities
of  virus (AD169wt131) for one hour. The virus–serum mixtures were then transferred to 96-well culture plates of ARPE-19 cells; the ﬁnal pre-neutralization quantities per
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tell  were 1000, 2000, 4000, or 8000 TCID50. Cell lysates were prepared using iScri
nalysis. Results of two representative human sera, (A) #11 and (B) #21, are shown
igh-throughput applications. The rate-limiting steps for conven-
ional PCR workﬂows are usually associated with sample nucleic
cid extraction/puriﬁcation. In our initial proof-of-principle study
sing SV40, a non-enveloped DNA virus, we successfully avoided
ample DNA puriﬁcation by subjecting diluted culture supernatant
rom virus-infected cells to SYBR Green qPCR [24]. In subsequent
tudies, we extended our approach to encompass RNA viruses
inﬂuenza virus and respiratory syncytial virus) [19,20]. Again, we
ircumvented the need for sample RNA puriﬁcation by using crude
ell lysates as input for one-step SYBR Green RT-qPCR to quantify
iral RNA. Recent studies suggest that crude cell lysates as input for
T-qPCR offer similar accuracy and superior sensitivity compared
ith puriﬁed RNA [25,26].
In the present study, we have developed a neutralization assay
or HCMV, an enveloped DNA virus. We  did not consider sampling
f culture supernatant for cell-released virus (as was done for SV40)
o be practical for HCMV because its infectivity typically remains
ell-associated. A decision was made to target cell-associated viral
NA rather than viral DNA because (1) choosing a highly expressed
NA would constitute an ampliﬁcation in itself and thus facilitate
etection/quantiﬁcation, and (2) viral DNA replication is restricted
o the cell nucleus and thus efﬁcient release of viral DNA may
equire harsher cell-lysis conditions. An RNA target for RT-qPCR
n the case of a DNA virus such as HCMV entails additional meas-
res to minimize signal contribution from viral DNA; this issue is
ot a concern for RNA viruses that have no DNA intermediates in
heir life cycle. One of our primers spans an exon–exon splice junc-
ion, which allows for speciﬁc quantiﬁcation of HCMV RNA with
inimal bias due to viral DNA.
Others have reported high-throughput cell-based assays for
CMV with a qPCR readout in the context of screening for antivi-
al compounds [27,28]. These assays target viral DNA in diluted cell
ysates rather than viral RNA, likely a deliberate choice by the inves-
igators as many of the antiviral compounds used in their studies
irectly inhibit viral DNA synthesis. Targeting viral DNA appears
o be associated with lengthening of the assay (assessment at 3–4ple Preparation Reagent and collected at 6 h post-infection followed by RT-qPCR
 point represents the mean with corresponding range (n = 2).
days post-infection) [27,28] compared with our approach of tar-
geting the IE1 RNA transcript. Furthermore, extraction of viral DNA
involves exposure of infected cells to a lysis buffer containing non-
ionic detergents and proteinase K for 1 h at 56 ◦C; subsequently
(following dilution), inactivation of proteinase K necessitates sam-
ple heating for 5 min  at 95 ◦C [27,28]. These steps can be a hindrance
to throughput. In contrast, preparation of cell lysates using our
approach involves cell exposure to lysis buffer for 2 min  at room
temperature; the resulting cell lysates can be directly used in RT-
qPCR without dilution or other processing steps.
Other existing high-throughput cell-based HCMV assays in com-
mon  use rely on endpoint assessment based on immunostaining for
cells expressing viral antigens [12,13,29,30] or measuring the activ-
ity of a reporter gene product (ﬂuorescent protein or luciferase)
driven by a recombinant virus [14,15,31,32]. Each has advantages
as well as drawbacks. Immunostaining involves many steps, which
can complicate adaptation to full automation. Moreover, optimiza-
tion of cell ﬁxation/permeabilization may  not be trivial [30], and
staining characteristics can be dependent on cell type [12]. Gener-
ation of recombinant reporter viruses can be cumbersome due to
the large size of the HCMV genome and thus may  not be conducive
to studies requiring the use of numerous HCMV strains.
Our RT-qPCR-based neutralization assay for HCMV has several
advantages. The generation of lysate samples can be achieved in
straightforward steps, and the assembly of downstream reactions
can be easily automated. The dynamic range of RT-qPCR contributes
to assay robustness in terms of variation in input virus dose (Fig. 5).
The inherent sensitivity of PCR coupled with choosing an abundant
immediate-early gene transcript as the target allows considerable
shortening of assay turn-around time with endpoint assessment
possible as early as 6 h post-infection. The HCMV IE1 gene may  be
sufﬁciently conserved such that our primers may  be applicable to
many HCMV strains [33]. In any case, designing suitable primers
de novo, if the need arises (for other strains or other viral gene
transcript targets), is usually straightforward. In addition to a muta-
tion in UL131, AD169 carries other genomic alterations secondary
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o adaptation in ﬁbroblasts that may  inﬂuence its neutralization
ehavior (for example, AD169 contains a large deletion in the ULb’
egion [34,35]); we intend to expand the scope of our analysis in
uture studies to include clinical isolates. Finally, assay establish-
ent in new laboratories would be facilitated by distribution of
rozen RNA reagents that can serve as calibration standards.
Cost may  be a constraint for throughput using our approach.
owever, we have actively pursued measures to mitigate lim-
tations arising from cost. For example, we have demonstrated
he feasibility of using a simple in-house lysis buffer as an alter-
ative to commercial reagents (Supplemental Fig. 2) [17]. Thus,
he per-sample cost of cell-lysate preparation can be essentially
liminated.
We observed that human sera positive for HCMV-speciﬁc
gG have substantially higher neutralizing activity (∼47-fold;
ig. 4 and Supplemental Table 1) when measured using epithe-
ial cells compared with using ﬁbroblasts. This is in agreement
ith prior studies [29,30,36,37]. The likely mechanism under-
ying this phenomenon is the cell-type dependent difference
n HCMV entry pathway. Recent data suggest that antibod-
es directed against the gH/gL/pUL128/pUL130/pUL131 complex
ay  comprise the majority of neutralizing activity in HCMV
yperimmune globulin preparations when assayed using epithe-
ial/endothelial cells [38]. It is notable that most investigational
CMV vaccines evaluated in humans thus far have not included the
H/gL/pUL128/pUL130/pUL131 complex in their repertoire of anti-
ens [11]. Targeting the gH/gL/pUL128/pUL130/pUL131 complex is
 recent and promising vaccination strategy [39–43].
High-throughput assays to measure HCMV-neutralizing activ-
ty in both epithelial/endothelial cells and ﬁbroblasts would be
ssential in support of vaccine development. Our assay may  be
traightforward enough such that transfer across laboratories may
ot be overly burdensome. Assay transferability would be desirable
articularly in early phases of development in which generation of
eroepidemiology data and evaluation of vaccine immunogenicity
ay  be conducted by multiple independent investigators.
. Conclusion
We  have demonstrated the feasibility of using an endpoint
ssessment based on RT-qPCR performed on crude lysates from
nfected cells to measure neutralizing activity against HCMV in both
pithelial cells and ﬁbroblasts. Neutralization titers associated with
CMV IgG positive human sera were substantially higher when
easured using epithelial cells compared with using ﬁbroblasts,
hus highlighting the need for an assay platform ﬂexible enough
o accommodate multiple cell types. Vaccine development may
e facilitated by high-throughput assays, such as our own, that
re capable of measuring cell-type dependent HCMV-neutralizing
ctivity while maintaining desirable features in terms of simplicity,
apidity, robustness, ﬂexibility, and transferability.
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